Showing 1 - 18 results of 18 for search '"CAPRISA"', query time: 0.06s Refine Results
  1. 1

    Assessing the safety and pharmacokinetics of the monoclonal antibodies, VRC07-523LS and PGT121 in HIV negative women in South Africa: study protocol for the CAPRISA 012A randomised controlled phase I trial by Nigel Garrett, Sharana Mahomed, Edmund Capparelli, Cheryl Baxter, Nonhlanhla Yende Zuma, Tanuja Gengiah, Derseree Archary, Penny Moore, Natasha Samsunder, Dan H Barouch, John Mascola, Julie Ledgerwood, Lynn Morris, Salim Abdool Karim

    Published 2019-07-01
    “…Going forward, the aim is to select the ideal dose and/or monoclonal antibody for co-formulation and testing with CAP256-VRC26.25LS, a potent monoclonal antibody against subtype C virus, in an efficacy trial.Methods and analysis CAPRISA 012A is a randomised, double blinded, placebo-controlled phase I trial to assess the safety and PK profile of two mAbs, VRC07-523LS and PGT121 administered SC to 35 young HIV negative women at low risk for HIV infection. …”
    Get full text
    Article
  2. 2
  3. 3
  4. 4

    Evaluation of Metronidazole Resistance of Vaginal Swab Isolates from South African Women Treated for Bacterial Vaginosis by Timo Schwebs, Ann-Katrin Kieninger, Lenka Podpera Tisakova, Vera Oberbauer, Rocío Berdaguer, Andile Mtshali, Gugulethu Mzobe, Anne Rompalo, Adrian Mindel, Marothi Letsoalo, Nigel Garrett, Sinaye Ngcapu, Lorenzo Corsini

    Published 2024-12-01
    “…<b>Background/Objectives</b>: The high recurrence rate of bacterial vaginosis (BV) after antibiotic treatment is at least partially attributed to resistant bacteria. The CAPRISA 083 (CAP083) study investigated the influence of metronidazole (MTZ) treatment on the vaginal microbiome in 56 South African women diagnosed with BV. …”
    Get full text
    Article
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18